Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01066611 | Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber | PHASE1 | COMPLETED | 48 | — | — | Jan 1, 2010 | Apr 1, 2010 | May 5, 2011 | 1 | Austria |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | CAL-263 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CAL-263 | DRUG | CAL-263 10 mg or placebo once daily for 7 days |
| Placebo | DRUG | CAL-263 10 mg or placebo once daily for 7 days |
Inclusion Criteria: 1. Age \>18 and \<55 years 2. Has a history of seasonal allergic rhinitis for at least 2 years 3. Has sensitivity to grass pollen demonstrated by a positive response to skin prick testing 4. Has a positive Radio Allergen Sorbent Test (class 2 or greater) for grass pollen during ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |